lactic acid has been researched along with Exanthema in 2 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Skripuletz, T | 1 |
| Pars, K | 1 |
| Schulte, A | 1 |
| Schwenkenbecher, P | 1 |
| Yildiz, Ö | 1 |
| Ganzenmueller, T | 1 |
| Kuhn, M | 1 |
| Spreer, A | 1 |
| Wurster, U | 1 |
| Pul, R | 1 |
| Stangel, M | 1 |
| Sühs, KW | 1 |
| Trebst, C | 1 |
| Muizzuddin, N | 1 |
| Marenus, KD | 1 |
| Maes, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center Clinical Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris[NCT03128723] | 45 participants (Actual) | Interventional | 2017-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cutaneous Tolerance Scores: Burning/Stinging (assessing skin burning/stinging), from Baseline to Day 14. Scale range is 0-3 where 0 = no burning/stinging, 1 = mild burning/stinging, 2 = moderate burning/stinging, and 3 = severe burning/stinging. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.02 |
Cutaneous Tolerance Scores: Burning/Stinging (assessing skin burning/stinging), from Baseline to Day 28. Scale range is 0-3 where 0 = no burning/stinging, 1 = mild burning/stinging, 2 = moderate burning/stinging, and 3 = severe burning/stinging. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Dryness/Scaling (assessing skin dryness), from Baseline to Day 14. Scale range is 0-3, where 0 = no dryness, 1 = mild dryness, 2 = moderate dryness, and 3 = severe dryness. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.11 |
Cutaneous Tolerance Scores: Dryness/Scaling (assessing skin dryness), from Baseline to Day 28. Scale range is 0-3, where 0 = no dryness, 1 = mild dryness, 2 = moderate dryness, and 3 = severe dryness. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.14 |
Cutaneous Tolerance Scores: Edema (assessing skin edema/swelling), from Baseline to Day 14. Scale range is 0-3 where 0 = no edema, 1 = mild edema, 2 = moderate edema, and 3 = severe edema. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Edema (assessing skin edema/swelling), from Baseline to Day 28. Scale range is 0-3 where 0 = no edema, 1 = mild edema, 2 = moderate edema, and 3 = severe edema. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Erythema (assessing skin redness), from Baseline to Day 14. Scale range is 0-3 where 0 = no redness, 1 = mild redness, 2 = moderate redness, and 3 = severe redness. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.09 |
Cutaneous Tolerance Scores: Erythema (assessing skin redness), from Baseline to Day 28. Scale range is 0-3 where 0 = no redness, 1 = mild redness, 2 = moderate redness, and 3 = severe redness. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.07 |
Cutaneous Tolerance Scores: Itching (assessing skin itching), from Baseline to Day 14. Scale range is 0-3 where 0 = no itching, 1 = mild itching, 2 = moderate itching, and 3 = severe itching. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.04 |
Cutaneous Tolerance Scores: Itching (assessing skin itching), from Baseline to Day 28. Scale range is 0-3 where 0 = no itching, 1 = mild itching, 2 = moderate itching, and 3 = severe itching. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Tightness/Dry Feeling (assessing skin tightness/dry feeling), from Baseline to Day 14. Scale range is 0-3 where 0 = no tightness/dry feeling, 1 = mild tightness/dry feeling, 2 = moderate tightness/dry feeling, and 3 = severe tightness/dry feeling. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.02 |
Cutaneous Tolerance Scores: Tightness/Dry Feeling (assessing skin tightness/dry feeling), from Baseline to Day 28. Scale range is 0-3 where 0 = no tightness/dry feeling, 1 = mild tightness/dry feeling, 2 = moderate tightness/dry feeling, and 3 = severe tightness/dry feeling. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.05 |
2 other studies available for lactic acid and Exanthema
| Article | Year |
|---|---|
Varicella zoster virus infections in neurological patients: a clinical study.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Exanthema; Female; Herpesvirus 3, Human; Humans; | 2018 |
Factors defining sensitive skin and its treatment.
Topics: Adult; Balsams; Cosmetics; Dermatitis, Contact; Dermatologic Agents; Epidermis; Erythema; Exanthema; | 1998 |